Kala Pharmaceuticals Current Ratio 2016-2021 | KALA

Kala Pharmaceuticals current ratio from 2016 to 2021. Current ratio can be defined as a liquidity ratio that measures a company's ability to pay short-term obligations.
Kala Pharmaceuticals Current Ratio Historical Data
Date Current Assets Current Liabilities Current Ratio
2021-06-30 $0.17B $0.03B 6.59
2021-03-31 $0.18B $0.02B 8.96
2020-12-31 $0.17B $0.02B 7.71
2020-09-30 $0.18B $0.02B 9.11
2020-06-30 $0.20B $0.02B 11.63
2020-03-31 $0.21B $0.02B 12.17
2019-12-31 $0.11B $0.03B 4.26
2019-09-30 $0.11B $0.02B 6.25
2019-06-30 $0.13B $0.02B 7.50
2019-03-31 $0.15B $0.02B 10.30
2018-12-31 $0.18B $0.02B 10.41
2018-09-30 $0.08B $0.01B 6.34
2018-06-30 $0.09B $0.01B 9.78
2018-03-31 $0.10B $0.01B 20.40
2017-12-31 $0.12B $0.02B 7.75
2017-09-30 $0.12B $0.01B 10.99
2017-06-30 $0.03B $0.01B 3.55
2017-03-31 $0.00B 0.00
2016-12-31 $0.00B 0.00
2016-09-30 $0.00B 0.00
2016-06-30 $0.00B 0.00
2015-12-31 $0.00B 0.00
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.117B $0.006B
Kala Pharmaceuticals, Inc. is a biopharmaceutical company. It focused on the development and commercialization of therapeutics through its nanoparticle-based Mucus Penetrating Particles technology. The Company designs proprietary drug delivery technology to penetrate mucosal tissue such as the eyes, lungs, gastrointestinal tracts and the female reproductive systems. Kala Pharmaceuticals, Inc. is based in Waltham, United States.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $129.416B 8.62
Bio-Rad Laboratories (BIO.B) United States $21.730B 46.31
QIAGEN (QGEN) Netherlands $12.526B 21.21
Biohaven Pharmaceutical Holding (BHVN) United States $9.249B 0.00
Emergent Biosolutions (EBS) United States $2.705B 6.53
Arcus Biosciences (RCUS) United States $2.404B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.873B 0.00
Myovant Sciences (MYOV) United Kingdom $1.831B 0.00
Zymeworks (ZYME) Canada $1.080B 0.00
Ambrx Biopharma (AMAM) United States $0.464B 0.00
SQZ Biotechnologies (SQZ) United States $0.372B 0.00
Enzo Biochem (ENZ) United States $0.161B 15.86